Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_assertion type Assertion NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_head.
- NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_assertion description "[Since Cot represents an alternative mode, independently of RAF, to activate Erk1/2, all these data strongly suggest that molecular targeting of Cot may be a potential new specific strategy for ALCL lymphomas therapy, without the fully disturbance of the Erk1/2 function.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_provenance.
- NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_assertion evidence source_evidence_literature NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_provenance.
- NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_assertion SIO_000772 21741362 NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_provenance.
- NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_assertion wasDerivedFrom befree-2016 NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_provenance.
- NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_assertion wasGeneratedBy ECO_0000203 NP908284.RAnG8iPiB4SbzYIaaHkacvq1rvr3x_Mf419qLIVFx_QXc130_provenance.